{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:43:20Z","timestamp":1759466600544,"version":"build-2065373602"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is a heterogeneous malignant plasma cell neoplasm. A significant increase in the bone marrow plasma cell percentage (BMPC%) may adversely affect prognosis. However, a high BMPC% has not been clearly defined. The Revised International Staging System (R-ISS) is considered the standard risk stratification model for newly diagnosed MM (NDMM) and is widely used to assess prognosis. However, a significant proportion of patients were categorized as R-ISS stage II due to high heterogeneity within the population, complicating the accurate prediction of prognosis. This study included 208 patients who were diagnosed with NDMM and received standardized treatment between January 2018 and May 2023, and were categorized into low, medium, and high BMPC% groups. The Kaplan-Meier method was utilized to estimate the progression-free survival (PFS) and overall survival (OS). The Cox proportional hazards model was used to estimate the relationship between BMPC% and survival in patients with R-ISS stage II. The results indicated that a high BMPC% significantly negatively affected OS (hazard ratio [HR] = 4.13, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.002), indicating an adverse prognostic factor. Compared with the low and intermediate BMPC% groups, the high BMPC% group exhibited the shortest median survival time (<jats:italic>p<\/jats:italic> &amp;lt;\u00a00.001). Additionally, we analyzed the effect of BMPC% on survival rates stratified by R-ISS stage. Within the stage II subgroup, the OS for the BMPC% stratified groups were NA, 50.1 months, and 29.6 months (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.01). We used external validation to confirm the reliability of the results. The results also indicated that a high BMPC% significantly negatively affected OS (<jats:italic>p<\/jats:italic>\u00a0&amp;lt;\u00a00.001). This study demonstrated that including a BMPC% \u2265 50% can enhance the predictive value of the R-ISS for NDMM, particularly in patients with R-ISS stage II.<\/jats:p>","DOI":"10.3389\/fonc.2025.1627653","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:11:23Z","timestamp":1759464683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement of revised international staging system risk stratification in patients with newly diagnosed multiple myeloma using a high bone marrow plasma cell percentage: a real-world study in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaoman","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongqin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094462","article-title":"The role of marrow microenvironment in the growth and development of Malignant plasma cells in multiple myeloma","volume":"22","author":"Giannakoulas","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.485","article-title":"Myeloma: management of the newly diagnosed high-risk patient","volume":"2016","author":"Dispenzieri","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3316-7","article-title":"Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients","volume":"97","author":"Gonz\u00e1lez-Calle","year":"2018","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.145078","article-title":"Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma","volume":"102","author":"Kastritis","year":"2017","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05806-9","article-title":"R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study","volume":"103","author":"Chu","year":"2024","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","article-title":"Increased bone marrow plasma-cell percentage predicts outcomes in newly diagnosed multiple myeloma patients","volume":"20","author":"Al Saleh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02791.x","article-title":"Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging","volume":"51","author":"Bartl","year":"1982","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910615)67:12<3150::aid-cncr2820671236>3.0.co;2-u","article-title":"Prognostic factors in multiple myeloma","volume":"67","author":"Cherng","year":"1991","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J anesthesiology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7673","article-title":"Defining and managing high-risk multiple myeloma: current concepts","volume":"18","author":"Costa","year":"2020","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000229","article-title":"High-risk multiple myeloma: how to treat at diagnosis and relapse","volume":"2021","author":"Mateos","year":"2021","journal-title":"Hematology Am Soc Hematology Educ Program"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A european myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1309493","article-title":"Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases","volume":"22","author":"Qian","year":"2017","journal-title":"Hematology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13897","article-title":"Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis","volume":"110","author":"Chen","year":"2023","journal-title":"Eur J haematology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090977","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","volume":"99","author":"Noll","year":"2014","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0061-9","article-title":"Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target","volume":"32","author":"Xu","year":"2018","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210910124319","article-title":"Role of the bone marrow microenvironment in drug resistance of hematological Malignances","volume":"29","author":"Hosseini","year":"2022","journal-title":"Curr medicinal Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05843-4","article-title":"TGF-\u03b2: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-\u03b2 in the microenvironment of multiple myeloma","volume":"103","author":"Xue","year":"2024","journal-title":"Ann Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70160","article-title":"Spleen involvement at diagnosis of multiple myeloma: A case report and literature review","volume":"8","author":"Fiorini","year":"2025","journal-title":"Cancer Rep (Hoboken N.J.)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0356","article-title":"CIC Mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement","volume":"25","author":"Da Vi\u00e0","year":"2020","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39698","article-title":"A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia","volume":"10","author":"Chng","year":"2024","journal-title":"Heliyon"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1627653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:11:24Z","timestamp":1759464684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1627653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1627653"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1627653","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1627653"}}